Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson iNVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, Q4 2022
91
Period ended Jan 1, 2023
Change on a year earlier
-24.2%
120 in Q4 2021
History
25 quarters
Since Q4 2016
Sources
17
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | INVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2022 | Jan 1, 2023 | 91 | -24.2% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2022 | Oct 2, 2022 | 109 | -18.0% | Form 10-Q (filed 2022-10-27) ↗ |
| Q2 2022 | Jul 3, 2022 | 120 | -25.0% | Form 10-Q (filed 2022-07-29) ↗ |
| Q1 2022 | Apr 3, 2022 | 128 | -14.7% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2021 | Jan 2, 2022 | 120 | -44.7% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2021 | Oct 3, 2021 | 133 | -40.6% | Form 10-Q (filed 2022-10-27) ↗ |
| Q2 2021 | Jul 4, 2021 | 160 | -10.6% | Form 10-Q (filed 2022-07-29) ↗ |
| Q1 2021 | Apr 4, 2021 | 150 | -14.3% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Jan 3, 2021 | 217 | +22.6% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2020 | Sep 27, 2020 | 224 | +25.1% | Form 10-Q (filed 2021-10-29) ↗ |
| Q2 2020 | Jun 28, 2020 | 179 | +1.1% | Form 10-Q (filed 2021-07-29) ↗ |
| Q1 2020 | Mar 29, 2020 | 175 | -13.4% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 29, 2019 | 177 | -22.4% | Form 10-K (filed 2022-02-17) ↗ |
| Q3 2019 | Sep 29, 2019 | 179 | -5.8% | Form 10-Q (filed 2020-10-23) ↗ |
| Q2 2019 | Jun 30, 2019 | 177 | -17.7% | Form 10-Q (filed 2020-07-24) ↗ |
| Q1 2019 | Mar 31, 2019 | 202 | -18.5% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 30, 2018 | 228 | -14.6% | Form 10-K (filed 2021-02-22) ↗ |
| Q3 2018 | Sep 30, 2018 | 190 | -28.3% | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jul 1, 2018 | 215 | -27.1% | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2018 | Apr 1, 2018 | 248 | -12.7% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 267 | -28.0% | Form 10-K (filed 2019-02-20) ↗ |
| Q3 2017 | Oct 1, 2017 | 265 | – | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2017 | Jul 2, 2017 | 295 | – | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2017 | Apr 2, 2017 | 284 | – | Form 10-Q (filed 2018-05-01) ↗ |
| Q4 2016 | Jan 1, 2017 | 371 | – | Form 8-K (a8k2017q4exhibit9915.htm, filed 2018-01-23) ↗ |
Breakdown
What makes up invokana / invokamet (canagliflozin) [reported separately through fy2022q4] — worldwide sales ($m)
- INVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — U.S. sales ($M)29 · Q4 2022
- INVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — International sales ($M)62 · Q4 2022
- INVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — Worldwide reported growth YoY (%)-24.1% · Q4 2022
- INVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — Worldwide operational (constant-currency) growth YoY (%)-19.6% · Q4 2022
Cite this data
StockData. (2026). Johnson & Johnson INVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — Worldwide sales ($M) ($M), quarterly Q4 2016–Q4 2022 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_invokana
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.